Equities

Panacea Biotec Ltd

PANACEABIO:NSI

Panacea Biotec Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)412.90
  • Today's Change2.90 / 0.71%
  • Shares traded113.89k
  • 1 Year change+153.31%
  • Beta0.9071
Data delayed at least 15 minutes, as of Nov 25 2024 06:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Panacea Biotec Limited is an India-based pharmaceutical and biotechnology company with research, manufacturing and marketing capabilities. The Company is engaged in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food and nutrition products in India and international markets. Its segments include vaccines and formulations. It has specialized in the development of fully liquid combination vaccines that can be stored at 2-8 degree Celsius temperature. Its vaccine portfolio includes EasySix (DTwP-Hib-HepB-IPV), EasyFive-TITM (DTwP-Hib-HepB), EasyFour-TI (DTwP-Hib), EasyFourPol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Its pipeline vaccines include NucoVac 11, DengiALL and Td (tetanus and diphtheria - reduced). Its pharmaceutical formulation products include Sitcom Tablets and Sitcom Cream. Its nutrition product brand names include ChilRunfull, ChilRun 7+ and ChilRun NoSucrose.

  • Revenue in INR (TTM)5.50bn
  • Net income in INR-148.63m
  • Incorporated1984
  • Employees1.15k
  • Location
    Panacea Biotec LtdB-1 Extn / G-3Mathura Road, Mohan Co-opIndlEstateNEW DELHI 110044IndiaIND
  • Phone+91 1 141679000
  • Fax+91 1 141679075
  • Websitehttps://www.panaceabiotec.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sigachi Industries Ltd4.36bn660.99m16.02bn991.0028.503.3920.603.681.691.6911.1114.150.62663.013.274,396,491.009.3614.7713.2519.5750.5050.3014.9314.921.396.470.25761.6132.0825.3431.3424.6470.35--
Jagsonpal Pharmaceuticals Ltd2.27bn243.00m16.91bn1.03k71.058.5759.277.458.988.9883.7874.420.97035.139.922,213,181.0010.3910.9512.4013.2958.1658.1310.719.212.6032.840.047443.81-11.834.58-15.9425.50-35.6982.06
JG Chemicals Ltd7.57bn550.05m16.92bn56.0029.243.8827.122.2314.7714.77202.34111.33------135,230,700.00--------17.29--7.56--11.46--0.0281---14.90---43.84------
Syncom Formulations (India) Ltd3.29bn331.47m18.33bn802.0048.035.8547.625.570.4060.4063.493.340.84856.213.624,105,761.008.547.5010.9910.2338.4934.1010.079.384.0912.050.0435--17.457.1226.1317.95----
Beta Drugs Ltd3.35bn410.00m20.04bn371.0048.8811.0839.265.9942.6542.65348.21188.131.264.043.749,022,873.0015.4215.1023.3522.2339.9539.7712.2512.381.5917.060.09530.0030.2135.0118.6235.29-10.89--
Windlas Biotech Ltd6.96bn612.28m20.10bn1.15k32.934.2624.862.8929.2029.20331.88225.631.066.074.436,028,180.009.30--13.64--37.52--8.80--1.6130.610.0388--22.97--36.51------
Amrutanjan Health Care Ltd4.38bn475.20m20.22bn635.0042.606.7937.544.6216.4316.43151.37103.001.196.8912.856,893,025.0012.8816.2216.4820.1250.0353.0910.8613.233.62217.880.007418.9510.9610.7112.9012.4626.9316.43
Hester Biosciences Ltd3.12bn234.69m20.29bn642.0084.086.7248.186.5028.3728.37368.62354.810.46171.223.234,862,882.003.896.154.917.6971.1366.648.4212.831.222.850.437123.2714.4511.33-29.06-14.591.49-11.42
SMS Pharmaceuticals Ltd7.68bn593.38m20.41bn1.20k34.313.6222.312.667.037.0391.0366.570.72781.814.186,420,048.005.555.438.407.3330.1033.307.627.870.71044.540.33616.1735.868.81805.824.478.419.86
IOL Chemicals and Pharmaceuticals Ltd.20.72bn1.19bn20.44bn2.78k17.24--11.060.986620.2020.20353.05--------7,461,253.00--14.91--19.4533.9634.545.7212.00--10.06--10.59-3.804.82-3.39-10.7035.27--
Panacea Biotec Ltd5.50bn-148.63m25.11bn1.15k--3.02125.784.57-2.46-2.4690.20135.980.43741.107.874,799,546.00-1.2210.26-1.6516.5363.2850.27-2.7924.871.03-13.780.02540.0021.574.1396.47--74.65--
Themis Medicare Ltd4.20bn529.90m26.64bn1.54k50.326.4741.636.345.755.7545.6344.760.73062.392.222,727,670.009.2111.1212.5716.4664.6460.3212.6114.961.56--0.16517.597.7415.75-23.51--26.73--
Indoco Remedies Ltd17.73bn320.40m29.49bn5.93k95.932.7121.641.663.343.34175.26118.230.81941.524.512,989,727.001.366.881.999.8568.3465.591.666.930.81421.710.433914.028.9113.41-30.78--34.5437.97
RPG Life Sciences Limited6.18bn706.60m32.94bn1.27k46.628.6836.655.3342.7242.72373.86229.381.221.998.444,868,662.0013.9216.0719.3521.7767.8562.9911.4311.991.45207.320.0029.2713.5012.0129.6051.9828.6046.14
Data as of Nov 25 2024. Currency figures normalised to Panacea Biotec Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.